Cann Group
Market Cap
AU$147.5m
Last Updated
2019/11/12 10:42 UTC
Data Sources
Company Financials +
Executive Summary
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution/supply of medicinal cannabis for a range of diseases and medical conditions in Australia.
Snowflake
Fundamentals
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Cann Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CAN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.5%
CAN
2.7%
AU Pharmaceuticals
1.2%
AU Market
1 Year Return
-60.8%
CAN
-31.8%
AU Pharmaceuticals
12.1%
AU Market
Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -31.8% over the past year.
Return vs Market: CAN underperformed the Australian Market which returned 12.1% over the past year.
Shareholder returns
| CAN | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | 2.7% | 1.2% |
| 30 Day | -24.4% | -0.5% | 2.0% |
| 90 Day | -45.6% | 3.5% | 3.2% |
| 1 Year | -60.8%-60.8% | -31.6%-31.8% | 18.3%12.1% |
| 3 Year | n/a | -42.5%-43.1% | 40.6%22.1% |
| 5 Year | n/a | -21.1%-28.2% | 54.2%19.8% |
Price Volatility Vs. Market
How volatile is Cann Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
When Will Cann Group Limited (ASX:CAN) Turn A Profit?1 month ago | Simply Wall St
Looking At Cann Group Limited (ASX:CAN) From All Angles2 months ago | Simply Wall St
How Much Of Cann Group Limited (ASX:CAN) Do Insiders Own?Valuation
Is Cann Group undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CAN (A$1.04) is trading below our estimate of fair value (A$7.44)
Significantly Below Fair Value: CAN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CAN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: CAN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAN is good value based on its PB Ratio (1.9x) compared to the AU Pharmaceuticals industry average (2.3x).
Next Steps
Future Growth
How is Cann Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
63.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: CAN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CAN's is expected to become profitable in the next 3 years.
Revenue vs Market: CAN's revenue (47.6% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: CAN's revenue (47.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAN's Return on Equity is forecast to be high in 3 years time (31.7%)
Next Steps
Past Performance
How has Cann Group performed over the past 5 years?
-35.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAN has high quality earnings.
Growing Profit Margin: CAN's current net profit margins (-419%) are higher than last year (-780.3%).
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of -35.9% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.9%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-14.14%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Cann Group's financial position?
Financial Position Analysis
Short Term Liabilities: CAN's short term assets (A$51.7M) exceeds its short term liabilities (A$4.8M)
Long Term Liabilities: CAN has no long term liabilities
Debt to Equity History and Analysis
Debt Level: CAN is debt free.
Reducing Debt: CAN has not had any debt for past 5 years.
Balance Sheet
Inventory Level: CAN has a high level of physical assets or inventory.
Debt Coverage by Assets: CAN's debt is not covered by short term assets (assets are -2799.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -83.7% each year
Next Steps
Dividend
What is Cann Group's current dividend yield, its reliability and sustainability?
2.52%
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CAN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Cann Group's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
Peter Crock 0
3.5yrs
Tenure
AU$1,591,786
Compensation
Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at CANN Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing an ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD1.09M) is above average for companies of similar size in the Australian market ($USD258.78K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.3yrs
Average Tenure
Experienced Management: CAN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
3.6yrs
Average Tenure
Experienced Board: CAN's board of directors are considered experienced (3.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 117,314 |
| Max Price | AU$2.25 |
| Entity | Company |
| Shares | 8,879 |
| Max Price | AU$2.11 |
| Entity | Company |
| Shares | 500,000 |
| Max Price | AU$2.32 |
| Entity | Individual |
| Role | Vice Chairman Deputy Chairman |
| Shares | 10,000 |
| Max Price | AU$1.83 |
| Entity | Individual |
| Role | Vice Chairman Deputy Chairman |
| Shares | 20,000 |
| Max Price | AU$2.06 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.
Management Team
Richard Baker
Company Secretary & CFO
- Tenure: 1.3yrs
- Compensation: AU$204.01k
Shane Duncan
General Manager of Commercial
- Tenure: 0.9yrs
- Compensation: AU$235.45k
Peter Crock
Chief Executive Officer
- Tenure: 3.5yrs
- Compensation: AU$1.59m
Steven Notaro
Head of Legal
- Tenure: 0yrs
- Compensation: AU$204.01k
Neil Gripper
General Manager of Operations
- Tenure: 1.3yrs
- Compensation: AU$210.65k
Board Members
Allan McCallum
Non-Executive Chairman
- Tenure: 0yrs
- Compensation: AU$90.95k
Doug Rathbone (73yo)
Independent Non-Executive Director
- Tenure: 4.7yrs
- Compensation: AU$47.30k
Philip Robert Jacobsen
Deputy Chairman
- Tenure: 0yrs
- Compensation: AU$47.30k
Neil Belot
Non-Executive Director
- Tenure: 1.8yrs
- Compensation: AU$46.67k
Geoff Pearce
Independent Non-Executive Director
- Tenure: 3.6yrs
- Compensation: AU$47.30k
Company Information
Cann Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cann Group Limited
- Ticker: CAN
- Exchange: ASX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$147.547m
- Shares outstanding: 141.87m
- Website: https://www.canngrouplimited.com
Location
- Cann Group Limited
- Walter and Eliza Hall Institute of Medical Research
- 4 Research Avenue
- Bundoora
- Victoria
- 3083
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CAN | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | May 2017 |
| CAN | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | May 2017 |
| CVJ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 2017 |
| CNGG.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | May 2017 |
Biography
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution/supply of medicinal cannabis for a range of d ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/12 10:42 |
| End of Day Share Price | 2019/11/12 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.